Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Shengjing Hospital is the lead sponsor of 46 current clinical trials in our China register. 34 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Carboplatin, Pyrotinib and Trastuzumab. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting3474%
Not yet open715%
Active, closed49%
By invitation12%

Trials by phase

Observational1941%
Not applicable1430%
Phase 2920%
Phase 424%
Phase 324%

Clinical trials sponsored by Shengjing Hospital

46 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer NCT05346510 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2022-03	China
Multi-parametric Magnetic Resonance Imaging for the Precise Diagnosis and Quantitative Study of Liver Steatosis, Inflammation, and Fibrosis in Chronic Liver Disease. NCT06463366 · ClinicalTrials.gov ↗ · Liver Stiffness	Observational	Recruiting	2022-06	China
Multifrequency MRE in Evaluation of Chronic Kidney Diseases NCT06202235 · ClinicalTrials.gov ↗ · Chronic Kidney Disease (CKD)	Observational	Recruiting	2022-10	China
3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features NCT06955208 · ClinicalTrials.gov ↗ · Meningioma	Not applicable	Recruiting	2022-10	China
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients NCT05635487 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer Drugs: Pyrotinib, Trastuzumab Rezetecan	Phase 2	Recruiting	2023-03	China
3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension NCT05475015 · ClinicalTrials.gov ↗ · Cirrhosis, Liver, Portal Hypertension, Advanced Chronic Liver Disease	Observational	Recruiting	2022-08	China
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer NCT04136782 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Albumin-Bound Paclitaxel, Carboplatin, Docetaxel	Phase 4	Recruiting	2021-07	China
Psychological Screening and Nursing of Twin Pregnancy NCT05182541 · ClinicalTrials.gov ↗ · Twin; Complicating Pregnancy, Psychology	Not applicable	Recruiting	2021-03	China
Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease NCT06452862 · ClinicalTrials.gov ↗ · Diabetic Kidney Disease	Observational	Recruiting	2024-06	China
The Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression NCT07779005 · ClinicalTrials.gov ↗ · Lung Caner	Observational	Recruiting	2019-02	China
Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy NCT05241119 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2021-11	China
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT NCT04137653 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Carboplatin, Nab-paclitaxel, Paclitaxel	Phase 3	Recruiting	2021-07	China
Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography NCT05482269 · ClinicalTrials.gov ↗ · Pulmonary Embolism and Thrombosis, Deterioration, Clinical, Artificial Intelligence	Observational	Recruiting	2011-01	China
Effect of Threshold Pressure-Loaded RMT + tTBS on Respiratory Function in SCI Patients NCT07050069 · ClinicalTrials.gov ↗ · Spinal Cord Injuries	Not applicable	Recruiting	2024-12	China
fNIRS-Driven Visual Feedback Training to Restore Walking After Stroke NCT07014891 · ClinicalTrials.gov ↗ · Stroke	Not applicable	Recruiting	2024-12	China
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases NCT06208397 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Observational	Recruiting	2023-12	China
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World. NCT05263570 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2022-08	China
Near-Infrared Imaging of Motor Imagery Effects in Spinal Cord Injury NCT07106060 · ClinicalTrials.gov ↗ · SCI - Spinal Cord Injury, Motor Imagery, Brain-Computer Interfaces	Not applicable	Recruiting	2025-01	China
MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment NCT05957679 · ClinicalTrials.gov ↗ · Spinal Cord Tumors	Not applicable	Recruiting	2023-01	China
Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC NCT05228951 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2022-02	China
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC NCT06165900 · ClinicalTrials.gov ↗ · Stereotactic Radiotherapy, Immunotherapy, Breast Cancer Drugs: Adebrelimab, Carboplatin	Phase 2	Recruiting	2023-09	China
A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA. NCT05098769 · ClinicalTrials.gov ↗ · Pulmonary Embolism and Thrombosis, Deterioration, Clinical	Observational	Recruiting	2021-01	China
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy NCT04476485 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2021-07	China
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients NCT04983121 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 2	Recruiting	2021-08	China
MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B NCT06779058 · ClinicalTrials.gov ↗ · Chronic Hepatitis B, Liver Fibrosis	Observational	Recruiting	2025-01	China
The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer NCT06698679 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2024-11	China
Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer NCT04065321 · ClinicalTrials.gov ↗ · Breast Neoplasms	Observational	Recruiting	2019-10	China
A Clinical Study of Hyperthyroidism in Children NCT06570967 · ClinicalTrials.gov ↗ · Hyperthyroidism Drug: Methimazole	Observational	Recruiting	2023-07	China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer NCT05638594 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Carboplatin, Dalpiciclib, Docetaxel	Phase 2	Recruiting	2022-12	China
Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion NCT05990244 · ClinicalTrials.gov ↗ · Glioma	Not applicable	Recruiting	2017-01	China
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension NCT06205992 · ClinicalTrials.gov ↗ · Cirrhosis, Liver Portal Hypertension	Observational	Recruiting	2022-08	China
Birth Cohort Study of China Medical University NCT03561766 · ClinicalTrials.gov ↗ · Twin; Complicating Pregnancy, Advanced Maternal Age Pregnancy, Scarred Uterus	Observational	Recruiting	2018-06	China
The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer NCT06690645 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2024-11	China
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230 · ClinicalTrials.gov ↗ · HR Positive/HER2 Low Breast Cancer Drugs: Adebrelimab, Trastuzumab Rezetecan	Phase 2	Recruiting	2024-08	China
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT NCT07768085 · Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis	Not applicable	Not yet open	2026-08	China
Combination Therapy of Anthracyclines for Children With Nephroblastoma NCT03892330 · ClinicalTrials.gov ↗ · 0.5-14 Year Old Children With Nephroblastoma Drugs: Doxorubicin, Liposomal doxorubicin, Pirarubicin	Phase 4	Not yet open	2019-06	China
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer NCT07795424 · ClinicalTrials.gov ↗ · Breast Cancer, HR Positive, HER2 Positive Breast Cancer Drugs: Culmerciclib, Letrozole, Pertuzumab	Phase 2	Not yet open	2026-09	China
Effect of Cerebellar Fastigial Nucleus Stimulation Combined With Sling Exercise on Motor Function in Hemiplegic Stroke Patients NCT07670936 · ClinicalTrials.gov ↗ · Stroke	Not applicable	Not yet open	2026-07	China
Combined Magnetic Stimulation and Ultrasound for Detrusor Overactivity in SCI NCT07704268 · ClinicalTrials.gov ↗ · Spinal Cord Injuries	Not applicable	Not yet open	2026-07	China
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer NCT06202313 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Drugs: Cadonilimab, Eribulin	Phase 2	Not yet open	2024-02	China
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy NCT04973319 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Pyrotinib, Trastuzumab	Phase 3	Not yet open	2021-08	China
Interventional AI-Human Collaboration for Steatotic Liver Disease Screening NCT07613827 · ClinicalTrials.gov ↗ · Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease, Liver Steatosis	Not applicable	By invitation	2026-02	China
MR Elastography in Intracranial Lesions: Feasibility & Accuracy NCT06916715 · ClinicalTrials.gov ↗ · Brain Neoplasms	Observational	Active, closed	2017-05	China
Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment NCT05132790 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Active, closed	2023-09	China
An Observational Study About Adverse Outcomes in Acute Pulmonary Embolism Patients NCT05481242 · ClinicalTrials.gov ↗ · Pulmonary Embolism and Thrombosis, Deterioration, Clinical	Observational	Active, closed	2011-01	China
Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial NCT04486911 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	2020-07	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Shengjing Hospital trials

21 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Shengjing Hospital trials

46 conditions

Breast Cancer15Pulmonary Embolism and Thrombosis3Deterioration, Clinical3Stroke2Twin; Complicating Pregnancy2Spinal Cord Injuries2Liver Fibrosis2 Breast Neoplasms2 Hepatocellular Carcinoma (HCC)1 Intrahepatic Cholangiocarcinoma (Icc)1Hepatic Metastasis1Hepatic Hemangioma10.5-14 Year Old Children With Nephroblastoma1HR Positive, HER2 Positive Breast Cancer1Brain Neoplasms1Liver Stiffness1Chronic Kidney Disease (CKD)1Meningioma1HER2-positive Breast Cancer1 Cirrhosis, Liver1 Portal Hypertension1Advanced Chronic Liver Disease1Psychology1Diabetic Kidney Disease1

By trial register

Register	Trials	Recruiting
Clinical trials in China	46	34

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10
Xijing Hospital	9

Sponsors with the most current trials registered for this condition.

Questions about Shengjing Hospital trials

How many clinical trials does Shengjing Hospital sponsor?

Shengjing Hospital is the lead sponsor of 46 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shengjing Hospital trials recruiting?

Yes. 34 of its 46 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shengjing Hospital testing?

Its current trials name 21 drugs and biologicals as interventions. The most frequent are Carboplatin (4), Pyrotinib (3), Trastuzumab (3), Adebrelimab (2) and Docetaxel (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Shengjing Hospital clinical trials